Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's Why

Pharvaris (NASDAQ:PHVS - Get Free Report) saw unusually-high trading volume on Monday . Approximately 189,848 shares were traded during trading, an increase of 157% from the previous session's volume of 73,937 shares.The stock last traded at $16.43 and had previously closed at $16.72.

Analyst Ratings Changes

Separately, Cantor Fitzgerald dropped their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th.

Pharvaris Trading Down 3.8%

The company's fifty day simple moving average is $15.52 and its 200 day simple moving average is $17.13. The firm has a market capitalization of $869.06 million, a P/E ratio of -5.94 and a beta of -2.86.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Palumbo Wealth Management LLC purchased a new position in Pharvaris in the 4th quarter worth about $196,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $111,000. JPMorgan Chase & Co. lifted its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Geode Capital Management LLC boosted its holdings in Pharvaris by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares during the last quarter. Finally, FMR LLC boosted its holdings in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.